Remove tag share-pricing
article thumbnail

Risk-sharing agreements are growing at a rate of 24%

Pharmaceutical Technology

On November 22, 2022, the FDA approved CSL Behring’s Hemgenix (etranacogene dezaparvovec), the first gene therapy treatment for hemophilia B, with a staggering manufacturer price of $3.5 million, according to GlobalData’s Price Intelligence (POLI), making it the most expensive drug in the world.

Marketing 105
article thumbnail

The current pharma business model is unsustainable

World of DTC Marketing

In pharma, growth depends on new products with hefty price tags when over 80% of voters want lower costs for their prescription drugs. The average American with cancer can do the math and come to the same conclusion that some oncology experts are coming to: Cancer drugs are priced too high.”

Pharma 210
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Do healthcare mergers and acquisitions lead to better care for patients?

Clarify Health

But consolidation in healthcare markets is not with its critics, with some experts raising concerns over increasing prices due to decreased competition and eliminating services. Shared expertise : Mergers and acquisitions are an opportunity to bring together the best of all involved.

Leads 52
article thumbnail

Axsome bounces back as FDA clears depression drug

pharmaphorum

Shares in Axsome Therapeutics have rocketed on FDA approval of its depression therapy Auvelity (formerly AXS-05) – a year after its approval was held up by the regulator.

FDA 95
article thumbnail

Upcoming sickle cell gene therapies cost effective at $2 million, says ICER

Pharmaceutical Technology

Two gene therapies up for approval this year for sickle cell disease could be cost effective in some cases at a $2 million price point, based on a draft evidence report published by the Institute for Clinical and Economic Review (ICER). Since the price of the therapies is unknown, the institute used a placeholder cost of $2 million.

article thumbnail

[Podcast] COVID Disruption & Its Indelible Mark on Healthcare Marketing

Healthcare Success

In the podcast, he shares valuable insights about how hospitals and health systems are coping with these changes, pivoting to meet the changing needs of the healthcare consumer, and building more transparent communication strategies for internal and external audiences. "We Alan shared, "It was probably three weeks before I felt normal again."

article thumbnail

Patent wars: what’s behind Amgen’s possible win over Sanofi at the US Supreme Court

Pharmaceutical Technology

Both drugs come with a high price tag. In its past statements shared with other outlets, Amgen stated that patents need to give researchers wide protection to incentivise new inventions. Both drugs are monoclonal antibodies that inhibit the protein PCSK9. Amgen sued the two companies in 2014 over supposed patent infringement.

Pharma 104